Status:
TERMINATED
[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.
Lead Sponsor:
Pfizer
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the long term (up to 2 years) safety and tolerability of \[S,S\]-Reboxetine in patients with pain after shingles.
Eligibility Criteria
Inclusion
- Patients must have pain present for more than 3 months after healing of the shingles skin rash.
- Patients at screening must have a score of \>/=40mm on the pain visual analogue scale.
Exclusion
- Patients with significant hepatic impairment.
- Patients with other severe pain, that may impair the self-assessment of pain due to postherpetic neuralgia (pain after shingles).
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00354094
Start Date
November 1 2006
End Date
October 1 2007
Last Update
November 8 2007
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tampa, Florida, United States, 33606
2
Pfizer Investigational Site
West Palm Beach, Florida, United States, 33407
3
Pfizer Investigational Site
Greensboro, North Carolina, United States, 27401
4
Pfizer Investigational Site
Fargo, North Dakota, United States, 58104